Clinical Care Options Oncology - Lung Cancer http://clinicaloptions.com/Oncology.aspx New treatment data and educatinal activities for Oncology and Hematology Clinicians en-us Clinical Care Options Oncology - Lung Cancer http://images.imedoptions.com/img.asp?img=cco/CCO_ONC_RSS.gif http://clinicaloptions.com/oncology Immunology for the Oncologist: Historical Review of Immune Dysregulation and Immune Strategies http://clinicaloptions.com/Oncology/Treatment%20Updates/Immunotherapy/Modules/Review.aspx F. Steven Hodi, MD, provides a historical look at previously used immunotherapy strategies and the novel and emerging strategies being employed today. Also included is a review of immune dysregulation that occurs in oncogenesis. Clinical Evidence: What Have We Learned From Targeting EGFR? http://clinicaloptions.com/Oncology/Treatment%20Updates/Pathways/Modules/Targeting%20EGFR.aspx Louis M. Weiner, MD, reviews current clinical trial data regarding EGFR-targeted therapeutic agents in the treatment of cancer. Expert Analysis of New Lung Cancer Data from Chicago http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Lung%20Cancer/Lung%20Cancer.aspx David S. Ettinger, MD, David R. Gandara, MD, and Corey J. Langer, MD, discuss lung cancer data from the clinical oncology meeting. Prophylactic Cranial Irradiation Decreases Risk for Brain Metastases and Death in Patients With Extensive-Disease Small-Cell Lung Cancer http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Lung%20Cancer/Capsules/4.aspx Randomized, controlled, phase III trial demonstrated prophylactic cranial irradiation increases overall and failure-free survival rates and reduces incidence of brain metastases in patients with SCLC-ED. Adding Bevacizumab to Chemotherapy Does Not Improve Survival in Elderly Patients With NSCLC http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Lung%20Cancer/Capsules/7535.aspx A retrospective, subset analysis of a phase III randomized trial showed that adding bevacizumab to paclitaxel/carboplatin chemotherapy regimen does not improve PFS or OS in patients with NSCLC older than 70 years of age. Combination Therapy With Bevacizumab, Etoposide, and Cisplatin Active in Small-Cell Lung Cancer, Extensive Disease http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Lung%20Cancer/Capsules/7564.aspx Preliminary results of a prospective, nonrandomized phase II study showed the addition of bevacizumab to standard etoposide/cisplatin chemotherapy improved response rates and progression-free survival in patients with extensive small-cell lung cancer Combination Irinotecan/Carboplatin Superior to Etoposide/Carboplatin in Small-Cell Lung Cancer With Extensive Disease http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Lung%20Cancer/Capsules/7523.aspx Randomized, phase III trial demonstrated that combination therapy with irinotecan/carboplatin vs etoposide/carboplatin prolonged median survival and doubled response rates in patients with small-cell lung cancer with extensive disease. Single Nucleotide Polymorphisms May Account for Increased Toxicity From,Irinotecan/Cisplatin Therapy in Patients With Small-Cell Lung Cancer With Extensive Disease http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Lung%20Cancer/Capsules/7524.aspx Significantly different toxicity profiles observed between patients with lung cancer in Japanese and US studies treated with irinotecan/cisplatin or etoposide/cisplatin may be due to SNPs Gene Expression Profiling Possibly Effective in Predicting Differential Response to Cisplatin and Pemetrexed in NSCLC http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Lung%20Cancer/Capsules/7501.aspx The development of predictors to cisplatin and pemetrexed resistance may be useful in determining patterns of resistance in patients with NSCLC. Gefitinib as Maintenance Therapy After Chemoradiation and Docetaxel Treatment May Negatively Impact Survival in Patients With NSCLC http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Lung%20Cancer/Capsules/7513.aspx Phase III, randomized SWOG 0023 trial demonstrates no survival benefit of gefitinib maintenance following chemoradiation and docetaxel in patients with stage III NSCLC. Addition of Bevacizumab to Gemcitabine/Cisplatin Improves Response and Progression-Free Survival in Advanced or Recurrent NSCLC Patients http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Lung%20Cancer/Capsules/LBA7514.aspx In a randomized, double-blind, phase III trial, the addition of bevacizumab to gemcitabine and cisplatin chemotherapy resulted in improved progression-free survival and higher response rates in patients with advanced or recurrent NSCLC. Cetuximab Increased Survival and Overall Response Rates When Used in Combination With Gemcitabine/Platinum-Based Chemotherapy in NSCLC Patients http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Lung%20Cancer/Capsules/7539.aspx Randomized, open-label, phase II trial demonstrates that addition of cetuximab to standard gemcitabine/platinum-based chemotherapy regimens may improve outcome in advanced NSCLC without compromising safety. Neoadjuvant Chemotherapy May Provide Clinical Benefit in Patients With NSCLC http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Lung%20Cancer/Capsules/7518.aspx EORTC 08012 phase III study in stage I-III NSCLC shows neoadjuvant chemotherapy to be well tolerated and associated with downstaging before surgery but has little impact on overall survival Consolidation Docetaxel After Chemoradiation Demonstrated No Survival Benefit and Increased Toxicity in Patients With Unresectable Stage III NSCLC http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Lung%20Cancer/Capsules/7512.aspx HOG LUN 01-24 phase III trial of consolidation docetaxel following chemoradiation in patients with unresectable stage III NSCLC demonstrated no survival benefit and increased toxicity vs observation arm. Gefitinib Survival Outcome Not Inferior to Docetaxel in Patients With Advanced/Metastatic or Recurrent NSCLC http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Lung%20Cancer/Capsules/LBA7509.aspx Randomized phase III trial showed that overall survival rate for gefitinib not inferior to docetaxel in patients with advanced or metastatic recurrent NSCLC. Preoperative Induction Chemotherapy Safe and Well Tolerated in Early-Stage NSCLC http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Lung%20Cancer/Capsules/7520.aspx Preoperative induction chemotherapy with paclitaxel/carboplatin safe and effective for patients with early-stage NSCLC in randomized phase III trial. Treatment Guided by ERCC1 and RRM1 Expression May Improve Response and Survival Outcomes in Patients With Advanced-Stage NSCLC http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Lung%20Cancer/Capsules/7502.aspx Prospective phase II trial demonstrates that chemotherapeutic treatment determined by ERCC1 and RRM1 mRNA expression may help optimize response and survival outcomes in patients with NSCLC. Docetaxel Therapy Administered Immediately After Gemcitabine/Carboplatin May Delay Disease Progression Without Added Toxicity Risk in Advanced-Stage NSCLC http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Lung%20Cancer/Capsules/7516.aspx Prospective, randomized phase III trial demonstrated that the administration of docetaxel immediately after gemcitabine/carboplatin significantly improved progression-free survival in patients with advanced-stage NSCLC without additional toxicity risk Adjuvant and Neoadjuvant Therapy for Early-Stage NSCLC http://clinicaloptions.com/Oncology/Management%20Series/NSCLC%20Research/Modules/Bunn.aspx Paul A. Bunn, Jr., MD, discusses adjuvant and neoadjuvant chemotherapy, targeted therapies, and priority trials in early-stage NSCLC. Novel Therapeutic Approaches http://clinicaloptions.com/Oncology/Management%20Series/NSCLC%20Research/Modules/Herbst.aspx Roy S. Herbst, MD, PhD reviews Epidermal Growth Factor Receptor Inhibitors, Antiangiogenic Agents, and Multikinase Inhibitors. First-Line and Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer http://clinicaloptions.com/Oncology/Management%20Series/NSCLC%20Research/Modules/Hirsch.aspx Topics include: Epidemiology of advanced NSCLC, current standard treatment for patients with advanced disease, and targeted agents for the first-Line treatment of NSCLC.